Start here if you're new
what it is
Werewolf Therapeutics is building cancer drugs designed to switch on inside tumors instead of attacking the whole body.
how it gets paid
Last year Werewolf Therap made $2M in revenue. collaboration and other revenue was the main engine at $2M, or 100% of sales.
what just happened
Full-year loss widened to $1.63 per share in 2024 from $1.05 in 2023.
At a glance
C+ balance sheet — struggling to keep the lights on
-$1.63 fy2024 eps est
$2M fy2024 rev est
1.5 beta
~$38M market cap
xvary composite: 29/100 — weak
What they do
Werewolf Therapeutics is building cancer drugs designed to switch on inside tumors instead of attacking the whole body.
The pitch is precision. Its PREDATOR platform aims to activate immune drugs mainly inside tumors, which means hitting cancer without blasting everything else. You get 4 named programs and 2 lead assets already in Phase I, but your moat here is scientific promise, not cash.
How they make money
$2M
annual revenue
collaboration and other revenue
$2M
WTX-124
$0M
WTX-330
$0M
other pipeline programs
$0M
The products that matter
tumor-activated immunotherapy platform
INDUKINE / PREDATOR platform
$2M · all reported revenue
it is the core platform and the source of the company's $2M of estimated revenue, but no program has reached Phase 2 trials. you are buying scientific optionality, not a commercial franchise.
pipeline only
Key numbers
$2M
2024 revenue
2024 revenue is estimated at just $2 million. So what: you are not buying sales here; you are funding a very early drug pipeline.
$1.63
2024 loss/share
The 2024 loss is estimated at $1.63 per share, worse than the $1.05 loss in 2023. So what: the business is moving farther from break-even, not closer.
$30M
long-term debt
Long-term debt stands at $30 million, or 44% of capital. So what: the balance sheet already has real weight for a company worth about $38 million.
5/100
price stability
A price stability score of 5 out of 100 tells you this stock barely holds still. So what: a small headline can move your position fast.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $30M (44% of capital)
C+ — balance sheet grade and long-term debt are flagged. this stock carries more risk than average.
Total return vs. market
Return history isn't available for HOWL right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Full-year loss widened to $1.63 per share in 2024 from $1.05 in 2023.
Quarterly EPS stayed negative all year: -$0.39, -$0.43, -$0.38, and -$0.46. Revenue is still tiny at an estimated $2M for 2024, so the income statement is mostly a spending story.
$0.46
q4 eps
$1.63
fy2024 eps
$2M
2024 revenue est.
the number that mattered
The move from a $1.05 loss in 2023 to a $1.63 loss in 2024 tells you costs are still outrunning the tiny revenue base.
source: quarterly EPS history and 2024 estimates
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is the strategic review ending without a buyer or partner. for HOWL, that is not a side issue. it is the thing standing between a stressed balance sheet and a much harder financing conversation.
med
no transaction emerges
The company announced on Feb 24, 2026 that it was exploring strategic alternatives. If that process ends without a deal, the market is left with the same facts it started with: $2M of estimated revenue, ongoing losses, and no approved product.
Impact: the strategic-review premium disappears and the stock goes back to trading on balance-sheet stress alone.
med
financing pressure and dilution
A $38M market cap with $30M of long-term debt and a C+ balance sheet leaves little room for error. If cash burn continues without a transaction, the next capital raise is unlikely to be shareholder-friendly.
Impact: new financing would support operations, but it could also come at a price that reshapes the ownership math for existing holders.
med
the platform does not translate beyond early data
WTX-613 Phase 1 data showed tumor-selective activation with reduced systemic toxicity. That's encouraging. It is not the same thing as late-stage clinical proof, and no program has reached Phase 2 trials.
Impact: if the science stalls, the company is left with only $2M of collaboration revenue and far less strategic value.
Put the pieces together and the picture is pretty simple: $2M of estimated revenue cannot support a $38M biotech with $30M of long-term debt forever. Either the transaction path works, or the capital structure becomes the whole story.
source: institutional data · regulatory filings · risk analysis
Pay attention to
deal math
strategic review outcome
The Feb 24, 2026 announcement is the live wire here. A buyer, partner, or asset sale changes the whole conversation. No deal means you are back to funding risk.
balance sheet
debt versus equity value
Long-term debt is $30M against a market cap of about $38M. That gap is tight enough that any financing update matters immediately to you.
calendar
the next corporate update
After the March 17, 2026 results, the next meaningful filing matters more than a routine quarter. The market wants deal progress, not just another status report.
consensus trend
2026 loss expectations
Consensus still points to -$0.35 EPS for 2026 with no revenue ramp flagged in the current page data. That is not a growth setup. It is a wait-for-resolution setup.
Analyst rankings
risk profile
high risk
risk rank 5 — significant risk of large drawdowns.
chart momentum
average
momentum rank 3 — the stock is moving with the broader market, no unusual signal.
source: institutional data
Institutional activity
institutional ownership data for HOWL is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$1
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive